Publications by authors named "C Benden"

Introduction: Current recommendations for lung transplantation immunosuppression do not explicitly target children, and many pharmacotherapies used in pediatrics are extrapolated from adults.

Methods: Data were collected from an anonymous survey distributed to International Pediatric Lung Transplant Collaborative (IPLTC) members from November 2023 to February 2024. Eligible participants included pediatric lung transplant physicians, pharmacists, or others with expertise in their lung transplant center's protocols.

View Article and Find Full Text PDF

Purpose Of Review: Lung transplantation (LTX) has transformed care for people with cystic fibrosis (pwCF) suffering from advanced cystic fibrosis lung disease (ACFLD), and it has evolved into an accepted therapy for patients with ACFLD across all ages. We review cystic fibrosis as a major indication for LTX, particularly highlighting outcomes including survival, a changing landscape over time, and factors affecting sequelae following LTX in cystic fibrosis.

Recent Findings: Although some populations such as those undergoing lung retransplantation exhibit inferior posttransplant outcomes, LTX for pwCF provides an excellent long-term survival that has significantly improved over time, likely due to specialized cystic fibrosis center care and recognition of common comorbidities in pwCF post-LTX.

View Article and Find Full Text PDF

Background: Racial and ethnic disparities in pediatric lung transplantation (LTx) related to the shifting cystic fibrosis (CF) population receiving highly effective modulator therapy (HEMT) has not been well investigated.

Methods: The UNOS Registry was queried for patients age 1-25 years undergoing bilateral LTx between 1 January 2012 and 31 December 2021. Race and ethnicity were classified as non-Hispanic White, non-Hispanic Black, Hispanic, or none of the above.

View Article and Find Full Text PDF
Article Synopsis
  • * Extracorporeal photopheresis (ECP) shows promise as a technique to modify immunosuppression and improve outcomes in organ transplant patients, including better graft survival rates and reduced side effects.
  • * The review emphasizes the need for more rigorous research, such as randomized controlled trials, to better understand the potential benefits of ECP in heart, lung, kidney, and liver transplants, as current data has gaps.
View Article and Find Full Text PDF